Proteologics, Ltd. Granted First siRNA Patent in the Ubiquitin Ligase Field

Published: Jan 09, 2008

REHOVOT, Israel--(BUSINESS WIRE)--Proteologics Inc. today announced that it has been granted United States Patent No. 7,268,227 relating to its leading antiviral program. This patent broadly covers siRNA molecules that can inhibit, or “silence” the expression of Proteologics’ antiviral drug target, hPOSH - a human protein that was characterized by Proteologics as a ubiquitin ligase essential for HIV biogenesis. Proteologics has anti-viral drug discovery programs based on proprietary research of host-protein ubiquitin-ligase drug targets shown to be essential for the HIV life cycle. Proteologics strategy is to target human pathways evolutionarily required for viral biogenesis consequently preventing completion of the viral life cycle in human cells. This new approach allows Proteologics to develop drugs that have not been previously encountered by viruses. Such new drugs are expected to be more effective than current therapies against the problematic emergence of viral resistance.

Back to news